Software Engineer Intern

MDLN investigation: Kessler Topaz Meltzer & Check, LLP encourages Medline Inc. (NASDAQ: MDLN) investors to contact the firm. Aug 13, 2026, 18:40 ET RADNOR, Pa., Aug. 13, 2026 /PRNewswire/ - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased or acquired Medline Inc. Class A common stock and experienced significant financial losses. Medline Reveals Significant FDA Violations On June 2, 2026, the FDA published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" Specifically, the FDA letter stated that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." According to a June 3, 2026 Reuters article, the latest FDA warning letter to Medline relates to "violations of manufacturing quality standards" and is "the second such action against the (C) ompany in two months." Further, the Reuters article states that according to the FDA, Medline "failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices." Why Did Medline's Stock Drop? Following the news of Medline's FDA violations, the company's stock price fell over 7%. Then, on August 5, 2026, Medline's stock price dropped by over 12% in response to the company's second quarter results and lowered full-year adjusted EBITDA guidance. Investors who purchased Medline Inc. (NASDAQ: MDLN) Class A common stock and experienced losses may have legal rights under the federal securities laws. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired Medline Inc. Class A common stock and have lost money on your investment, please provide your information here: https://www.ktmc.com/mdln-medline-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=mdln&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP

News for rocket scientists. NASDAQ: MDLN investigation reminder: Kessler Topaz Meltzer & Check, LLP encourages Medline Inc. (NASDAQ: MDLN) investors to contact the firm. RADNOR, Pa., Aug. 7, 2026 /PRNewswire/ - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who purchased or acquired Medline Inc. Class A common stock and experienced significant financial losses. Medline Reveals Significant FDA Violations On June 2, 2026, the FDA published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" Specifically, the FDA letter stated that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." According to a June 3, 2026 Reuters article, the latest FDA warning letter to Medline relates to "violations of manufacturing quality standards" and is "the second such action against the (C) ompany in two months." Further, the Reuters article states that according to the FDA, Medline "failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices." Why Did Medline's Stock Drop? Following the news of Medline's FDA violations, the company's stock price fell over 7%. Then, on August 5, 2026, Medline's stock price dropped by over 12% in response to the company's second quarter results and lowered full-year adjusted EBITDA guidance. Investors who purchased Medline Inc. (NASDAQ: MDLN) Class A common stock and experienced losses may have legal rights under the federal securities laws. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired Medline Inc. Class A common stock and have lost money on your investment, please provide your information here: https://www.ktmc.com/mdln-medline-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=mdln&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for its clients and the classes they represent. May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP

Medline Industries, LP issues nationwide recall of Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits. When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Summary. * Company Announcement Date: - August 05, 2026 * FDA Publish Date: - August 06, 2026 * Product Type: - Medical Devices * Reason for Announcement: - Due to heated wire connector (pigtail) at the Neptune humidifier may exhibit discoloration, melting, smoke, burning odor, or other signs of localized thermal damage * Company Name: - Medline Industries, LP * Brand Name: - Medline, Teleflex * Product Description: - Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits Company Announcement. On July 13, 2026, Medline Industries, LP initiated a nationwide recall of Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits. Medline received reports of sporadic failures involving the electrical connector of certain neonatal and infant heated wire breathing circuits. In affected circuits, the heated wire connector (pigtail) at the Neptune humidifier may exhibit discoloration, melting, smoke, burning odor, or other signs of localized thermal damage. To date, reported events have occurred infrequently relative to the number of devices distributed, with the observed occurrence rate of 0.011% across the distributed population. Refer to the below photographs of the product and a defect that was reported to Medline. The Neptune humidifier is designed with safety features that continually monitor the heated wire circuit and automatically discontinues power to the heated wires when electrical abnormalities are detected. When power to the heated wires is disconnected, respiratory gas flow to the patient continues. The disconnection of power is limited to the heated wire function. Continued delivery of inadequately heated or unconditioned gas can desiccate and damage the airway epithelium, predisposing the infant to bronchospasm, inspissated secretions, and airway obstruction. Potential continued loss of heated wire function may result in increased circuit condensation (rainout), which can cause inadvertent positive end-expiratory pressure (PEEP), circuit obstruction, or accidental lavage of pooled fluid into the infant's airway, reduced humidity and delivery of cold, dry gas increases the risk of cold stress, leading to elevated oxygen consumption and worsening respiratory distress. Consumers who have the affected Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits should stop using and discard the device. Consumers should not return product to Medline. Medline voluntarily recalled product after thorough investigation of reports received for this issue and notified the FDA of this action. At this time, Medline is not aware of any serious health consequences which have occurred due to use of the device. Recalled Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits were manufactured on or before July 8, 2026 and distributed from June 28, 2021, to July 31, 2026. Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits within the scope of the recall can be identified by their product labeling, which includes the name of the device, item number, and manufacturing date. The labeling of products affected by the recall include either a Teleflex or Medline item number, depending on the manufacturing date. Affected products manufactured before January 2024 display a Teleflex label and item number, while products manufactured starting January 2024 or later display a Medline label and item number. Please refer to the example labels below to identify the manufacturing date (red) and item number (blue) on the product label. The following item numbers are included in the scope of the recall: | Medline Item Number | Teleflex Item Number | | HUD78001KIT | 780-01KIT | | HUD78007 | 780-07 | | HUD78007KIT | 780-07KIT | | HUD78008KIT | 780-08KIT | | HUD78009 | 780-09 | | HUD78009KIT | 780-09KIT | | HUD78013 | 780-13 | | HUD78014 | 780-14 | | HUD78015 | 780-15 | | HUD78017KIT | 780-17KIT | | HUD78018 | 780-18 | | HUD78018KIT | 780-18KIT | | HUD78019 | 780-19 | | HUD88001KIT | 880-01KIT | | HUD88013KIT | 880-13KIT | | HUD88014KIT | 880-14KIT | | HUD88015KIT | 880-15KIT | | HUD88017KIT | 880-17KIT | All product manufactured on or after July 9, 2026 are not under scope of the recall and may continue to be used. Medline is notifying its distributors and customers by email and/or first-class mail and is arranging for credit of all recalled product(s). Consumers with questions regarding this recall can contact Medline by phone at 866-359-1704 Monday through Friday between the hours of 8am and 5pm CST or [email protected]. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this medical device. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. * Complete and submit the report Online: www.fda.gov/medwatch/report.htm * Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-3321088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 Company contact information.